Redeye: Sdiptech Q3 2022 - High Discount to Peers
Redeye retains its positive view on Sdiptech following a Q3 report that was in line with our expectations. We believe organic sales and EBITA growth will rebound, which we believe will reduce the increased discount to peers
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking.